Monday, 25 Sep 2017

You are here

Biologic Use in Adult-Onset Still's Disease

 Adult-onset Still's disease (AOSD) is the adult continum of systemic-onset juvenile idiopathic arthritis (SoJIA). Treatment of this febrile polyarticular systemic disorder can be complex, but has been relieved by several specific biologic therapies.

Currently there are no drugs (including biologics) specifically approved for use in AOSD, yet there are several that approved for use in SoJIA - indicated for use in active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older:  

Approved Biologics for SoJIA

  • Ilaris (canakinumab) 
  • Actemra (tocilizumab) 

Biologics Not Approved (but occassionally used)

  • Arcalyst (rilonacept) is an interleukin-1 blocker 
  • Kineret (anakinra): is an IL-1 receptor antagonist

Biologics Under Study (according to clinicaltrials.gov)

  • Ilaris (canakinumab) - under study for AOSD
  • Kineret (anakinra): under study for AOSD and SoJIA

A recent systematic review of the literature identified those biologic drugs that have been studied in AOSD. The meta-analysis included 19 observational studies and showed overall rate of clinical response of 0.85 (95% CI: 0.77-0.91, p < 0.0001) and an overall rate of complete remission of 0.66 (95% CI: 0.54-0.77, p = 0.01). These studies were hampered by a high rate of heterogeneity (Q=59.82 with df=19.0,p<0.0001,I2=68.23%).

Most of these results are driven by the success of IL-1 or IL-6 inhibition in controlling the systemic features of Still's disease - including fever, rash, hepatosplenomegaly, lymphadenopathy, arthritis, serositis and aggressively inflammatory indices.

TNF inhibitors are NOT effective enough to warrant use in those with active inflammatory systemic disease, but may be considered in those whose disease has settled into a dominant rheumatoid-like chronic, polyarthritis.

Disclosures: 
The author has received research/grant financial support on this subject

Add new comment

More Like This

Rituximab Efficacy in IgG4 Related Disease

PLOS reports  greater than 90% efficacy when rituximab (RTX) is used to treat patients with IgG4-related disease (IgG4-RD). 

Jak Inhibition May Ameliorate Pruritus

Interleukin-4 has been shown to activate sensory neurons involved in pruritus, and that inhibition of IL-4 with Jak inhibition significantly alleviates itching.

New Recommendations on Biosimilar Use

The introduction of a growing number of biosimilars into the market poses a substantial change in cost of care for patients with inflammatory rheumatologic disorders.  

Turnabout for Baricitinib

Eli Lilly and Company and Incyte Corporation announced today that, after discussions with the U.S. Food and Drug Administration in late August 2017, Lilly will resubmit a revised New Drug Application for baricitinib before the end of January 2018. The resubmission package will include new safety and efficacy data. 

Canakinumab Reduces CV Outcomes in High Risk Patients

The results of a randomized, double-blind trial have shown that canakinumab (CAN), an interleukin-1β inhibitor, given as 150 mg every 3 months, resulted in a significantly lower rate of recurrent cardiovascular events (in high-risk CV patients), independent of lipid-level lowering. The results of the CANTOS studywere simultaneously published in NEJM, Lancet and were presented at the European Society of Cardiology meeting in Barcelona.